Regeneron steps up opposition to Kymab’s human rat patent
Appeals
2019-08-26 12:47 pm
| Melbourne
US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
For information on rights and reprints, contact subscriptions@lawyerly.com.au